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Measles virus is a highly contagious virus causing acute and persistent diseases in man, the receptor of which is still 
not weil characterized. We have isolated a monoclonal antibody (mAb), designated mAb 119, which specifically inhibits 
measles virus infection of susceptible celllines in a dosa-dependent manner. This antibody precipitates a protein with 
an apparent molecular mass of 75 kDa from 1251 surface-labeled cells and its epitope is present on human peripheral 
blood mononuclear cells, human celllines, and the African green monkey cellline Vero. Affinity chromatography of 
detergent-solubilized cell membrane proteins over a Sepharose column with covalently bound mAb 119 led to the 
partial purification of the 75-kOa protein. Preincubation of measles virus with this affinity-purified protein inhibited 
measles virus infection dose dependently. Aminoacid microseq,uencing of this protein revealed its identity with the 
human membrane-organizing extension spike protein moesin, a protein intra- and extracellularly associated with the 
plasma membrane of cells. Subsequently, an antibody raised against purified moesin (mAb 38/87) was also found to 
specifically inhibit measles virus infection of susceptible cells and confirmed our data obtained with mAb 119. Our data 
suggest that moesin is acting as a receptor for measles virus. e> 1994 Academic Press, lnc. 
INTRODUCTION 
Measles virus (MV) is a highly successful pathogen 
and is responsible for the disease measles, classically 
a childhood community-related disease. The acute 
disease. which is largely self-limiting, gives life long 
immunity to MV, a situation which is aided by the exis-
tence of a single immunetype of MV. However, life 
threatening diseases can occur following exposure to 
MV and include acute measles encephalitis, measles 
inclusion body encephalitis (MI BE), and subacute scle-
rosing panencephalitis (SSPE). which target the central 
nervaus system with devastating effect. The tropism of 
the virus in acute measles is directed largely to epithe-
lial cells of the respiratory tract and cells of the immune 
system, i.e., lymphocytes and macrophages (for re-
view see Casah et al., 1989). By comparison, in brains 
of SSPE and MIBE patients MV has been detected 
mainly in neurons, but also in oligodendrocytes, astro-
cytes, microglial cells, and endothelial cells (Esiri et al., 
1981; Kirk et al., 1991; Haase et al., 1985; Moench et 
al., 1988; Schneider-Schaulies and ter Meulen, 1992). 
As a member of the Morbilliviruses, MV posesses an 
envelope that surrounds the viral nucleocapsid which 
contains one copy of a single-stranded negative sense 
RNA genome. The virus envelope has two virus-en-
coded glycoproteins inserted into it: the hemagglutinin 
1 To whom reprint requests should be addressed. 
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(H) protein, which mediates both virus attachment to 
susceptible cells and the biological activity of hemag-
glutination, while the fusion (F) protein, in conjunction 
with MV-H, is responsible for cell entry and fusion (Wild 
et al., 1991 ). Natural MV infection is limited to humans, 
although monkeys can be infected under experimental 
conditions, thus suggesting the presence of a MV cell 
receptor that is unique to higher primates. 
The primary event for successful infection of a cell by 
the virus involves attachment to the target cell and 
subsequent uptake of virus particles. This process is 
usually, although not exclusively, mediated by a spe-
cific virus receptor on the cell surface, which, depend-
ing on their distribution, may influence virus tropism 
(White and Littman, 1989). Viral receptors have been 
established for a growing number of viruses and recent 
evidence suggests that many viruses can utilize addi-
tional and/or alternative receptors for the attachment 
to cells (Dveskler et al., 1993; Harouse et al., 1989, 
1991; Lentz, 1990; Schneider-Schaulies et al., 1992). 
For MV there have been a number of studies per-
formed in an attempt to define its cellular receptor 
(Krah 1989, 1991; Harrewe et al., 1990, 1992; Yoshi-
kawa et al., 1991 ). Putative receptors were found tobe 
present on human cells, Vero cells, and monkey eryth-
rocytes and most likely to consist of glycosylated pro-
teins. ldentification by gel electrophoresis of the pro-
tein species involved in attachment of MV to suscepti-
ble cells was, un1ortunately, largely inconc\usive (Krah, 
0042-6822/94 $5.00 
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1991 ). However, in a recent study, a monoclonal anti-
body (mAb) was developed against a specific human 
cell surface protein which was found to inhibit MV in-
fection (Naniche et al., 1 992). The mAb immunoprecip-
itated a protein with the apparent molecular mass of 
57/67 kDa. The protein, which was designated gp57/ 
67, was subsequently identified as the membrane co-
factor protein or CD46 (Naniche et al., 1993b). How-
ever, CD46 is not present on all cells susceptible to MV 
infection, suggesting the presence of an additional re-
ceptor species. ln this study we have characterized a 
protein which is immunoprecipitated by a mAb, which 
specifically inhibits to a high degree the infection of a 
wide range of cells by MV. The immunoaffinity-purified 
protein binds MV and has been identified as the mem-
brane-organizing extension spike protein, moesin. 
These data implicate moesin as a further receptor spe-
cies for attachment and uptake of MV into susceptible 
cells. 
MATERIALS AND METHODS 
Cell culture 
Adherent celllines (human astrocytoma U-251, hu-
man cervical carcinoma Hela, human neuroblastarne 
SKN-MC, African green monkey kidney Vero) were 
propagated and maintained in Eagles minimal essen-
tial medium (EMEM) supplemented with 5% fetal calf 
serum. Human monocyte cell line U-937 and primary 
human peripheral blood mononuclear cells (PBMC) 
were maintained in RPMI 1640 supplemented with 
10% fetal calf serum, 2.0 g/liter sodium bicarbonate, 
0.1 g/liter penicillin, 0.1 g/liter Streptomycin, 1 mM so-
dium pyruvate, nonessential amino acids, BME vita-
mins and 2 mM L-glutamine (all Seromed). 
Viruses 
The Edmonston strain of MV was used throughout 
the experiments with virus stocks prepared according 
to Schneider-Schaulies et al. (1993}. Additional viruses 
(canine distemper virus CDV, poliovirus serotypes 1, 2, 
and 3, Coxsackie viruses 82 and 84, and Echovirus 11) 
were propagated as above, except for the freeze-thaw 
step which was omitted for the enteroviruses. 
Culture and selection of monoclonal antibodies 
Monoclonal antibodies were raised against cell sur-
face epitopes by inoculating BALB/c mice intraperito-
neally (i.p.) with 1-2 x 106 U-251 cells. Four weeks 
later the mice were boosted with a further i.p. inocula-
tion of U-251 cells and followed 1 month later by a final 
challenge intravenously, 3-4 days prior to harvesting 
the spleen. BALB/c spleen cells were fused with the 
myeloma cell line Sp2/0-Ag 14 and seeded into 96-well 
dishes for selection of hybridomas. Hybridoma cells 
were grown in RPMI 1640 medium as described ear-
lier. 
Screening of hybridoma cells for those secreting 
mAbs that inhibit infection by MV was performed in 
microtiter plates. Supernatants of hybridoma cultures 
were added to confluent Vero cells {3 x 1 04 per weil) in 
microtiter plates 30 min prior to infection with MV 
(m.o.i. = 0.1) and incubated for 2 days at 37° .Inhibition 
of virus-induced cytopathic effect was observed micro-
scopically. Protein-G column-purified mAbs were 
stored at -20° at a concentration of 1 mg/ml for use. 
The mAb 38/87 raised against the membrane-organiz-
ing extension spike protein. moesin, was described 
(Lankes et al., 1988). Antibodies to MHC class I (W6/ 
32) and CD58 (LFA-3) were purchased {Dianova) and 
mAbs to MV-H (K83), MV-F (A504), and U85 (raised 
against U-251 cells) were prepared in the Iabaratory 
and purified over protein-G columns. 
Plaqueformationinhibition test 
This testwas performed on both Vero and U-251 cell 
monolayers in six-well plastic dishes (1 X 106 cells per 
weil}. Confluent cell monolayers were washed with 
PBS and 1 00 JLI of hybridoma cell supernatant (clarified 
by centrifugation at 300 g for 5 min) or specific concen-
trations of purified antibodies were added. After incu-
bation at room temperature for 45 min, the monolayers 
were washed once with PBS and 1 00 J.tl of PBS con-
taining 1 00 PFU of MV was added to each test weil. 
Further incubation at room temperature for 1 hr was 
followed by washing with PBS prior to overlaying the 
wells with 5 ml of EMEM supplemented with 1 o/o fetal 
calf serum and 1 o/o Noble agar (Sigma). Plaques were 
visualized after 3-5 days of incubation at 37° by stain-
ing with neutral red. 
Rosetting assay 
Rosetting assays were made with 1 05 U-937 cells in 
100 I-LI culture medium and incubated for 1 hr at 4 o with 
either mAb 38/87 or mAb 11 9 or with the control mAbs 
W6/32 (MHC class 1 specific) and U85 (nonbinding) (all 
0.5 mg/ml). After washing with PBS, 50 hemagglutinat-
ing units of MV was adcled followed by incubation for 1 
hr at 4 °. The cells were washed with PBS and resus-
pended in 200 J.tl PBS containing monkey erythrocytes 
at a final concentration of 0.1 o/o and incubated for 1 hr 
at 37°. Rosettes were defined microscopically as cells 
with three or more erythrocytes attached to the surface 
and results normalized to 0% inhibition against the 
nonbinding mAb U85. 
Inhibition of vaccinia virus MV-H/F-mediated fusion 
As an additional rapid screening assay for infection 
inhibiting mAbs we used a vaccinia virusdouble recom-
binant encoding both MV-H and -F proteins (VV-H/F, 
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Wild et al., 1991; a kind gift from T. F. Wild, Lyon, 
France}. mAbs were screened for their ability to inhibit 
the rapid and characteristic cell fusion associated with 
the expression of MV-H and -F proteins. Briefly, cells 
(U-251, He La or Vero) were seeded into 48-well cluster 
plates (1 x 106 per weil) and grown to confluency. The 
monolayers were washed with PBS and dilutions of 
mAb supernatant added to each test weil and incu-
bated at room temperature for 30 min. After incuba-
tion, W-H/F at an m.o.i. of 0.1 PFU was added and 
incubation for 18 hr at 37° made before fixing the cell 
monolayers with 3.5% paraformaldehyde in PBS and 
determining the inhibition of syncytium formation 
under the microscope. 
Flow cytometry analysis 
Flow cytometric analysis was performed as de-
scribed (Schneider-Schau lies et al., 1992). Briefly, 2 X 
1 05 cells were incubated for 45 min on ice with 200 ~I 
mAb. Cells were washed three times in FACS buffer 
(PBS containing 0.4% BSA and 0.02% sodium azide) 
and incubated with 200 ~I of a 1: 1 00 dilution of fluores-
cein isothiocyanate-conjugated goat anti-mause imm u-
noglobulin (Dako) on ice forafurther 45 min. After three 
washes with FACS bufferas before, flow cytometric 
analysiswas performed on a FACScan (Beeten Dickin-
son). For intracellular staining of epitopes, cells were 
fixed and permeabilized prior to application of the first 
antibody with 3.7% paraformaldehyde, 0.25% Triton 
X-1 00 in PBS for 5 min and unspecific binding was 
blocked by FACS buffer containing 1 0% BSA. 
Surface labeling of cells with 1251 
Surface iodination of cells (1 x 107 cells/500 J.LI) with 
500 "'Ci 1251 was performed using the Iodegen method 
and the manufacturers protocol (Pierce). Following io-
dination, the reaction was quenched with 30 mM so-
dium iodide after which the cells were washed three 
tim es with PBS and resuspended in Iysis buffer ( 1 0 mM 
Tris, pH 7 .4, 150 mM sodium chloride, 0.5% deoxycho-
late, 0.5o/o Triton X-1 00, 0.05% SOS) containing pro-
tease inhibitors (1 0 U aprotinin, 1 mM PMSF). After 
vigoraus mixing for 30 sec and incubation on ice for 1 5 
min. the lysates were centrifuged at 15,000 gfor 30 min at 
4 o and the supernatant was stored at -70° for use. 
lmmunoprecipitations 
lmmunoprecipitations were performed according to 
Schneider-Schaulies et al. (1992} with the following 
modifications. All lysates were precleared prior to im-
munoprecipitation by the addition of 5 ~I normal mouse 
serum and incubated on ice for 1 hr. Mouse immuno-
globulins were precipitated by adding 30 J.LI of packed 
protein A-Sepharose beads (Pharmacia) bound to rab-
bit anti-mause immunoglobulins for 30 min on ice fol-
lowed by centrifugation. Precipitates were analyzed by 
separation on 1 O% SDS-containing polyacrylamide gels 
{SOS-PAGE) and exposure of the dried gels to a phosphor 
imager (Molecular Dynamics) screen for 1 6 hr. 
Cell membrane preparation 
All procedures for the preparation of cell membranes 
were performed at 4 o in the presence of protease inhib-
itors to minimize any degradation of sensitive protein 
structures. Anchorage-dependent cells were removed 
nonenzymatically from the culture flask with Ca2+ and 
Mg2+ free PBS plus 1 mM EDTA, while suspension 
cells were pelleted by low speed centrifugation (200 g 
for 5 min). Cells were washed twice with Ca2+ and 
Mg2+ free PBS before resuspending the pellet in Butter 
I (Ca2+ and Mg2+ free PBS, 1 Oo/o sucrose, 2 mM EDTA, 
and 1 mM PMSF) and centrifuging for 1 hr at 22,000 
rpm in an SW55 roter (Beckman) to pellet vesicles. The 
pellet was gently resuspended in hypotonic Butter II 
(50 mM phosphate butter, pH 7.4, 1 mM PMSF) and 
centrifuged for 30 min at 14,000 rpm in an SW40 rotor 
(Beckman) to allow for the increased volume of buffer. 
The resulting pellet was resuspended in Iysis buffer 
(PBS plus 1.5% octylglucoside, 1 mM PMSF) at a ratio 
of 3 ml/g wet cell mass and incubated on ice for 1 hr. 
The lysate was centrifuged at 35,000 rpm for 1 hr in an 
SW55 rotor (Beckman), after which the supernatant 
was carefully removed and dialyzed overnight against 
PBS with 0.1% octyl glucoside before aliquoting and 
storage at -70°. Total protein concentration was de-
termined using the bicinchoninic acid method (Sigma) 
with typicat yields irom 1 g o1 wet cell mass equalling 
10-15 mg/ml. 
lmmunoaffinity purification of proteins 
Specific immunoaffinity purification of cell mem-
brane proteins by mAb was achieved using standard-
ized protocols form manufacturers. Protein-G-purified 
mAb was linked to activated Sepharose 48 beads 
{Pharmacia) to form an immunoaffinity matrix. Deter-
gent-extracted cell membranes {see above) were then 
passed over the mAb column at 4 o and bound proteins 
eluted with a sodium chloride step gradient. The eluted 
fractions were dialyzed against PBS (for biological anal-
ysis) or 10 mM Tris (for biochemical analysis). 
Amino acid sequencing 
For direct N-terminal amino acid sequencing, the af-
finity-purified proteinwas applied to a 1 0% SOS-PAGE 
gel. separated, and analyzed after electroblotting onto 
Glassybond (Biometra, Göttingen) according to Eck-
erskorn et al., 1988. For internal sequencing the pro-
tein was cleaved in the gel with protease Lys C (Boeh-
ringer, Tutzing). the peptides eluted and separated by 
reversed-phase HPLC on Superspher 60 RP select B. 
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FIG. 1. Inhibition of MV infection by mAb 119. The reduction in 
virus titer following pretreatment of cell monolayers with mAb 1 1 9 
was determined by plaque inhibition assay (1 00 PFU test). The per-
centage of infectivity was determined by comparison to mock-
treated (PBS) cell monolayers for each virus. An inhibition of infection 
was specifically detected for MV, but not for CDV, Polio 1, 2. 3, Echo 
11, and Coxsackie 82, 84. 
125 X 2 mm {Eckerskorn and Lottspeich, 1989). Amino 
acid sequence analyses were performed on a 4 77 A 
pulse liquid phase sequencer equipped with a 120A 
PTH analyzer (Applied Biosystems, Weiterstadt). 
RESULTS 
Isolation of antibodies inhibiting MV infection 
BAL8/c mice were immunized with human astrocy-
toma cell line U-251, these cells being highly suscepti-
ble to infection with MV strain Edmonston and sup-
porting its replication to high titers {1 06 PFU/ml). Ap-
proximately 3000 antibody producing hybridoma 
clones were assayed for their ability to inhibit MV infec-
tion using a rapid infection inhibition test in microtiter 
plates (see Materials and Methods). One clone which 
efficiently inhibited MV infection, and also recognized 
an epitope on the surface of U-2 51 cells as determined 
by flow cytometry (not shown), was subcloned three 
times by limiting dilution until a stable antibody produc-
ing clone was isolated. The mAb secreted by this clone 
was designated mAb 119. ln the following experiments 
the mAb was used as a purified fraction from a protein-
G column. 
Inhibition of MV infection following treatment of cell 
monolayers with mAb 119 was found tobe specific for 
MV alone after repeating 1 00 PFU plaque reduction 
tests with a number of different viruses. The data in Fig. 
1 show ttlat MV infection of Vero cells is inhibited by 
92% after pretreatment of the monolayer with mAb 
119. A similar Ievei of inhibition of MV infection (90%) 
by mAb 119 was observed on U-251 cells (data not 
shown). ln comparison, no inhibition of virus infection 
was seen for the related morbillivirus canine distemper 
virus (CDV), polio serotypes 1, 2, and 3, Echovirus 11, 
and Coxsackie viruses 82 and 84 in similar assays. 
Therefore, mAb 119 exhibits properties characteristic 
and coincident with a receptor-blocking antibody and 
represents an ideal instrument with which to identify 
the cell surface protein involved in this specific interac-
tion. 
lmmunoprecipitation of a 75-kDa protein with mAb 
119 
Todetermine the molecular mass of the putative MV 
cell receptor molecule, surface proteins of the human 
monocyte cellline U-937, which expresses high Ieveis 
of the mAb 119 epitope, were Iabeted with 1251. mAb 
119 precipitated a protein of an apparent molecular 
weight of 75 I<Da from U-937 cells (Fig. 2, lanes 4 and 
5). A protein of the same apparent molecular weight 
could be precipitated from Hela, U-251, and Vero cells 
(data not shown). 8ecause the cells were radioiodin-
ated, the protein precipitated by mAb 1 19 is expected 
to be expressed on the surface of cells and hence be 
able to interact with external ligands. By Western blot 
analysis of U-937 celllysates. mAb 119 was unable to 
FIG. 2. lmmunoprecipitation of 1251-labeled cell surface proteins 
with mAb 119. Cell surface proteins of U-937 cells were iodinated 
and celllysates immunoprecipitated with mAb 119 and an antibody 
to MHC class I as control. The precipitates were separated by 1 Oo/o 
SOS-PAGE and exposed to a phosphor imager screen for 1 6 hr. 
Lane 1, 14C-Iabeled protein markers: lane 2. U-937 celllysate precipi-
tated with PBS as negative control: lane 3. U-937 celllysate precipi-
tated with the MHC class 1-specific mAb W6/32; lane 4, U-937 cell 
lysate precipitated with mAb 1 19 (1 0 p.g/ml): lane 5. U937 celllysate 
precipitated with mAb 119 (1 00 p.g/ml). The mAb 119 specifically 
precipitated a molecule with the apparent molecular mass of 75 
kDa. 
MOESIN IS A MEASLES VIRUS RECEPTOR 269 
detect the 75-kDa protein, suggesting that protein 
conformation is vital (data not shown). 
Affinity purification of putative receptor molecules 
ln order to identify the protein precipitated by mAb 
119 by microsequencing and to further characterize it 
biologically, it was necessary to obtain I arge amounts 
of purified protein. To achieve this, mAb 119 was cova-
lently bound to activated Sepharose to form a matrix for 
affinity chromatography. Detergent (octyl glucoside) 
solubilized cell membranes from U-937 cells were cir-
culated over the column for 18 hr at 4 o prior to washing 
the column free of unbound proteins. Elution of bound 
proteins from the column was achieved using a NaCI 
step gradient and the eluate was then further concen-
trated with polyethylene glycol. The proteins were ana-
lyzed by SOS-PAGE and stained with Coomassie blue 
(Fig. 3). The predominant protein species was eluted 
with 300 mM NaCI and possessed the same apparent 
molecular mass as the immunoprecipitated (75 kDa) 
protein (Fig. 3, lanes 4 and 6). The yield of purified 
protein from the immunoaffinity column was typically 
200-250 ,ug per 20 mg total protein loaded. 
Biological activity of the enriched 75-kDa protein 
The immunoaffinity-purified protein likely contains a 
receptor binding motif for MV and by inference should 
effectively bind MV in solution, if protein conformation 
2 3 4 5 6 7 
FIG. 3. lmmunoaffinity purification of the 75-kDa protein. Deter-
gent-derived celllysate from U-937 cells was passed over an immu-
noaffinity column supporting mAb 119. Proteins binding to the affin-
ity column were eluted by a NaCI step gradient and analyzed by gel 
electrophoresis and subsequent staining with Coomassie blue. 
Lane 1, molecular weight markers; lane 2, detergent-solubilized 
U-937 cell membrane preparation; lane 3, unbound proteins after 16 
hr circulation over the column; lane 4, 300 mM NaCI eluate; lane 5, 
500 mM NaCI eluate; lane 6, polyethylene glycol-concentrated 300 
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FIG. 4. Reduction of the infectivity of MV after incubation with solu-
ble immunoaffinity enriched 75-kDa protein. The immunoaffinity col-
umn-enriched 75-kDa protein and bovine serum albumin (BSA) as 
control were diluted in PBS to yield a range of concentrations be-
tween 0 and 2 mg/ml. Dilutions of MV were mixed with a constant 
protein concentration and incubated for 1 hr an ice, and residual 
infectivity was determined by the plaque assay. The results obtained 
were normalized by setting the infectivity obtained in the presence of 
BSA to 1 00%. The solid line represents MV titrated against the 75-
kDa protein, whereas the broken line represents BSA plus MV. 
has been maintained. Therefore, the ability of the 
enriched 75-kDa protein to bind MV was assayed by 
infection inhibition tests. MV was titrated against con-
stant concentrations of the 75-kDa protein diluted in 
PBS and incubated for 1 hr an ice. As control. the 75-
kDa protein was replaced with similar concentrations 
of bovine serum albumin (BSA). After incubation, the 
residual infectivity was determined by the standard 
plaque assay. End-point titration of MV against the puri-
fied protein yielded an accurate estimate of the degree 
of virus binding. A reduction in virus infectivity between 
0.95 and 1.1 log 10 PFU/ml was observed for MV incu-
bated with purified protein of concentration 200 mg/ml 
(Fig. 4). This represents an overalllass of MV infectivity 
due to binding toprotein of approximatety 90%. Lower 
concentrations of purified protein gave less dramatic 
reductions in MV infectivity titer (Fig. 4). lncubation of 
MV with BSA under the same conditions did not re-
duce the virus infectivity titer. Likewise, similar assays 
performed with the morbillivirus CDV revealed no re-
duction in the virus infectivity titer (data not shown). 
Aminoacid sequencing of the isolated protein 
N-terminal amino acid microsequencing was per-
formed after separation of the eluted proteins from the 
mAb 119 immunoaffinity column by SOS-PAGE con-
taining approximately 50-100 ~-t9 of the 75-kDa pro-
tein. The Coomassie-stained 75-kDa band was ex-
cised and digested in the gel with protease Lys C and 
blotted onto Glassybond (Biometra, Göttingen) for se-
quencing of internal peptides. Three peptides, one at 
the amino,terminus and two internal, were sequenced. 
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F!G. 5. Dose-dependent inhibition of MV infection after pretreat-
ment of cell monolayers with mAb 119 and mAb 38/87. Vero cell 
monolayers (1 x 106 cellslwell) were incubated with dilutions of 
mAbs 119 and 38/87 in PBS as indicated and washed with PBS prior 
to infection with MV. The percentage of inhibition ot plaque forma-
tion was plotted against the concentration of mAbs 119 (solid line) 
and 38/87 (broken line}. Mean values of three experiments with stan-
dard deviations are shown. 
Comparison of the sequences of the peptides with the 
sequences available in the EMBL data base showed 
that all three peptides were identical to peptides of the 
cloned human protein moesin (membrane-organizing 
extension spike protein, Lankes and Furthmayer, 
1 991 ). The peptides correspond to amino acids 1-8 
{PKTISVRV). 132-137 (KYGDFN), and 500-513 (KDR-
SEEERTTEAEK) of human moesin which is comprised 
of 576 amino acids in total with a calculated molecular 
mass of 67 kDa. 
Inhibition of MV infection by moesin-specific 
antibodies is dose dependent 
To confirm the data obtained with mAb 119, the 
moesin-specific mAb 38/87 was included in subse-
quent experiments. The inhibition of MV infection fol-
lowing treatment of cell monolayers with mAbs 119 or 
38/87 was determined using the plaque inhibition as-
say. Half-maximal inhibition of MV infection on Vero 
cells was achieved after treating cell monolayers with 
approximately 1 5 ~g/ml of mAb 119 (45% plaque inhibi-
tion), while maximal inhibition was observed with ~50 
~tglml (~90% plaque inhibition) of the mAb (Fig. 5). 
Comparable results were obtained when the assay 
was performed on other human cell lines (data not 
shown). A similar dosa-dependent curve, albeit much 
reduced in comparison to the data for mAb 119, was 
observed with the moesin-specific antibody mAb 38/ 
87. Half-maximal inhibition of MV infection with this 
antibody was achieved with 30 ~g/ml (27% plaque inhi-
bition) while maximal inhibition required 90 ~g/ml (54% 
plaque inhibition; Fig. 5). Our data show that mAb 119 
and mAb 38/87 recognize different epitopes on moe-
sin, mAb 38/87 recognizing a linear epitope detected 
in Western blot as described (Lankes et al., 1988), 
whereas mAb 11 9 recognizes a conformational epi-
tope. 
Distribution of the epitopes on MV susceptible cell 
lin~s and primary cells 
The expression of the epitopes recognized by mAbs 
119 and 38/87 on the surface of human primary PBMC 
and various human and nonhuman cell lines was in-
vestigated by flow cytometry. The percentage of cells 
stained with mAb 119 above the negative control, fol-
lowing labeling with a fluorescein-conjugated second 
antibody, varied between 40 and 98% for the human 
cells examined (Fig. 6). The African green monkey kid-
ney cells (Vero), which are routinely used to propagate 
MV, were positive to approximately 50% (Fig. 6). ln 
comparison, mAb 38/87 exhibited a different staining 
pattern. Foreach cell line tested, the Ievei of expres-
sion of the mAb 38/87 epitope was much reduced, 
varying between 14 and 38% (Fig. 6). These results 
correlate weil with the reduced ability of mAb 38/87 to 
inhibit MV infection in the infection inhibition test (Fig. 
5). ln cantrast to the surface staining of cells, every cell 
human 
FIG. 6. Distribution of the epitopes of mAbs 119 and 38/87 on the 
surface of human and monkeycelllines. Flowcytometrywas used to 
determine the distribution of the epitopes recognized by mAb 119 
and mAb 38/87 on the surface of a number of different celllines. The 
Y axis shows the percentage of cells stained above background, the 
open boxes representing values for mAb 119 and the shaded boxes 
mAb 38/87. Peripheral blood mononuclear cells (PBMC) and U-937 
monocytes revealed the highest Ieveis of surface moesin expression 
detected by mAb 119, whereas U-251 cells (astrocytoma), SKN-MC 
cells (neuroblastoma), and Vero cells {African green monkey kidney) 
expressed the epitope for mAb 119 to a lasser extent. 
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of the cell lines investigated so far strongly expresses 
moesin intracellularly with equal intensities detected 
with either mAb 119 or mAb 38/87 (data not shown). 
Inhibition of MV binding to cells 
ln order to investigate the question of whether moe-
sin is involved in the attachment of MV to cells, mAbs 
38/87 and 119 were tested in rosetting assays for their 
ability to inhibit MV binding to monkey red blood cells. 
lncubation of U-937 cells with mAb 38/87 led to 52± 
3% reduction in the number of rosettes whilst mAb 119 
gave 67 ± 5% reduction in. rosette formation when 
compared to control mAbs fN6/32 (9 ± 2%) and non-
binding U85 (0 ± Oo/o) (n = 3). 
Inhibition of vaccinia virus MV-H/F-mediated fusion 
The MV-Hand -F glycoproteins are both required for 
fusion activity of cellular membranes (Wild et al., 1991 ). 
ln the rapid screening for new antibodies we found that 
mAb 119 inhibited fusion of recombinant vaccinia virus 
MV-H/F-infected U-251, Heia, and Vero cells (not 
shown). ln addition, mAb 38/87 inhibited fusion of vac-
cinia virus MV-H/F-infected U-251 cells (Fig. 7), Heia, 
and Vero cells (not shown). These data suggest that in 
addition to the epitope recognized by mAb 119, the 
less accessable cell surface moesin epitope of mAb 
38/87 is also functionally active in inhibition assays of 
MV fusion. 
Downregulation of surface moesin expression on 
MV-infected cells 
The degree of surface and intracellular expression of 
moesin in uninfected and persistently MV-infected 
cells was determined by flow cytometry. Persistently 
infected U-937 cells revealed a considerable reduction 
of the signal intensity for surface moesin (Fig. BA, com-
pare signal 1 and 2). ln comparison, the expression of 
the MV fusion protein (MV-F) was detected exclusively 
on infected cells (Fig. 88, signal1 represents the nega-
tive control and signal 2 that of anti-MV-F mAb A504}, 
and the expression of MHC class I molecules was un-
altered following infection (Fig. SC). The intensity of the 
intracellular expression of moesin was not affected by 
the infection with MV (not shown). These data suggest 
that moesin is downregulated from the surface of in-
fected cells. but unaltered intracellularly. 
DtSCUSSION 
ln this report we have described a mAb (mAb 119) 
that is directeg against an epitope expressed on the 
surface of a number of human and primate cells and 
inhibits the binding of MV to its cell receptor, MV glyco-
protein-mediated fusion and, hence, infection of the 
FIG. 7. Inhibition of vaccinia virus MV-H/F-mediated fusion by anti-
badies ta moesin. U-251 cells were infected with a vaccinia virus 
recambinant expressing MV-H and -F (m.o.i. = 0.1) far 24 hr in the 
presence of 20 ,ug/ml of the unrelated antibody G26 to lymphocyte 
function-associated antigen (LFA-3) as negative contral (A), 20 ~g/ml 
mAb 38/87 to moesin (B), and 20 ,ug/ml mAb K83 to MV-H as positive 
contral (C}. Extensive fusion with large syncytia was obseNed exclu-
sively in cultures treated with the control antibady (A). Bar, 1 00 ~m. 
normally susceptible cell. The epitope recognized by 
mAb 119 is widely expressed to high Ievels on human 
and primate cells and the antibody was found to specifi-
cally inhibit MV infection. The mAb precipitates a 75-
kDa protein, which was identified as the human mem-
brane-organizing extensionspike protein, moesin.lt is 
this protein which we believe plays an integral role in 
the binding and uptake of MV to susceptible cells 
based on the evidence in this study. 
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F1G. 8. Downregulation of surface moesin expression after infec-
tion of cells with MV. The intensity of the surface expression of moe-
sin on uninfected U-937 cells (signal 1 J and U-937 cells persistently 
infected with MV (signal 2) was measured by flow cytometry. Cells 
were stained with mAb 38/87 to moesin (A). with mAb A504 recog-
nizing MV-F as a control of infection (B), and with mAb W6/32 to 
MHC class I as a control for the staining procedure (C}. The cell 
number (Y axis) was plotted against the fluorescence intensity <X 
axis}. 
Recently, a glycoprotein with the mass of 57/67 kDa 
was identified with the aid of a monoclonal antibody as 
a putative MV receptor (Naniche et al., 1992). This mol-
ecule has been identified as the human membrane co-
factor protein (CD46) present on many cells of human 
origin (Naniche et al., 1993b). The described antibody, 
MCI20.6, recognizing CD46, inhibits MV binding in a 
rosetting assay, reduces infection of Hela cells by MV, 
and inhibits cellular fusion mediated by vaccinia virus-
expressed MV-Hand -F proteins (Naniche et al., 1992). 
MV infection also led to the downregulation of C046 
on the cell surface and moreover, it was found that the 
MV-H protein was responsible for this phenomenon 
(Naniche et al., 1993a). Since specific receptor down-
regulation following infection has been observed for 
several viruses with differing receptor molecules, this 
finding, in addition to our own observation concerning 
the downregulation of moesin, add support to the hy-
pothesis that CD46 and moesin act as receptors for MV. 
CD46 is known to exist in as many as 14 different 
isoforms through alternative splicing of the cDNA (Rus-
se II et al., 1992) and it is unknown whether or not all 
these isoforms are able to act as receptor for MV. ln-
deed, the poliovirus receptor is known to be widely 
distributed throughout human cell types although the 
virus is able to infect only a select number of cell types 
(Ziebert and Wimmer, 1992). lt is believed that correct 
post-transcriptional and post-translational modification 
of the po\iovirus receptor by individual cells is neces-
sary to bind virus (Ziebert and Wimmer, 1992). ln the 
case of MV, cells which do not express human CD46 
and are not recognized by CD46-specific antibodies, 
such as some mouse cell lines. are readily infectable 
with MV (Rager-Zisman et a/., 1984) pointing to the 
existance of further receptor molecules like moesin, 
homologs of which are expressed by cells of murine 
origin. 
The protein moesin was initially identified as a cell 
surface component and thought to act as receptor for 
binding heparin and heparin sulfate (Lankes et a/., 
1988). Subsequent cloning of its cDNA and further 
analysis has revealed that moesin is largely localized at 
the inner side of the plasma membrane {Lankes et al., 
1991 ). Neither a signal sequence or a transmembrane 
domain could be identified by sequence analysis, sug-
gesting that it is not incorporated into the plasma 
membranein the classical way (Lankes et a/., 1991). 
Following the identification of moesin as the protein 
precipitated by mAb 119, we acquired a mAb (38/87) 
specific for the protein moesin that was used to charac-
terize this protein (Lankes et al., 1988, 1 991 ). From the 
outset it was known that these two mAbs recognized 
very different epitopes of the protein moesin. By FACS 
analysis. the epitope oi mAb 119 was found to be 
widely distributed an the surface of human and primate 
cells, whereas the epitope of mAb 38/87 was detected 
to a much lower degree an the surface of cells (Fig. 7). 
lmportantly, by Western blot analysis, only mAb 38/87 
is able to detect moesin, suggesting that mAb 119 rec-
ognizes a conformational epitope. Crucial evidence 
supporting the hypothesis that moesin is acting as a 
receptor for MV came from the ability of mAb 38/87 to 
inhibit MV infection of susceptible cells. Moreover. this 
mAb inhibited cell fusion following infection with re-
combinant vaccinia-expressed MV-H and -F protein, 
MOESIN IS A MEASLES VIRUS RECEPTOR 273 
and inhibited rosette formation by MV and by flow cyto-
metric analysis was downregulated on MV-infected 
cells, similar to that observed with the putative MV re-
ceptor CD46 (Naniche et al., 1993a}. The above crite-
rion fulfill the basic requirements for receptor blocking 
activity and mirrors the results obtained with mAb 119. 
The Ievei of infection inhibition by mAb 38/87 was 
somewhat less than that observed with mAb 119 and 
can be correlated to the accessability of the epitopes 
for each specific antibody on the surface of cells. As 
mentioned earlier, moesin is mainly localized on the 
internal side of the cell membrane which becomes ap-
parent when cells are permeabilized prior to staining 
with antibodies. lt is possible that the mode by which 
mAb 38/87 inhibits MV binding is by blocking MV ac-
cess to the conformational mAb 119 site following at-
tachment to its cell surface-expressed motif. This is 
current/y being investigated. 
A further important observation that points to moe-
sin as a putative receptor for MV is based on the Obser-
vation that the purified protein binds MV itself. This is 
not unusual given that, for example, soluble CD4 has 
been shown to inhibit the infection of certain cell types 
with HIV (Orloff et al., 1993). lnterestingly, in the case 
of HIV, alternative receptors which are not inhibitable 
by soluble CD4 can be used in the brain and by muscle 
cells (Ciapham et al., 1989}. ln addition, the results 
presented in this study point to the fact that more than 
one molecule is Hkely to be acting as receptors for MV. 
To gain entry into cells, MV utilizes two major protein 
species, the H and F proteins. and both are required for 
fusion of cells (Wild et a/., 1991 ). lt may be that the 
initial receptor interaction is mediated by a single spe-
cific receptor species with MV-H, followed by contact 
of the virus with a secend receptor (F interaction) to 
initiate successful infection. Our data show that there 
is a specific interaction between MV and moesin and 
that the critical motif is conformational and expressed 
on the cell surface. The question of whether moesin 
and CD46 are alternative receptors or part of one re-
ceptor complex is currently under investigation. 
Moesin, as weil as its homologs of the ERM {ezrin-
radixin-moesin) gene family have been shown to be 
localized at cell-to-cell adherens junctions, cleavage 
furrows, microvilli, and ruffling membranes (Sato et a/., 
1992). Most intense staining was found at the cleav-
age furrows in the mitotic phase of the cell cycle and 
could point to a correlation with the cell cycle depen-
dence of infection with MV. Furthermore, the concen-
tration of ERM proteins at cell-to-cell adhesion junc-
tions and cleavage furrows ·and their interaction with 
actin (Sato et al., 1992). mediating the association of 
actin filaments with the plasma membrane, suggest a 
direct connection between actin filaments and MV. 
How moesin is involved in the attachment and uptake 
of MV is an intriguing question which is under investi-
gation. 
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